Scholars@Duke

Mutant IDH1 is required for IDH1 mutated tumor cell growth.

Publication ,  Journal Article
Jin, G; Pirozzi, CJ; Chen, LH; Lopez, GY; Duncan, CG; Feng, J; Spasojevic, I; Bigner, DD; He, Y; Yan, H
Published in: Oncotarget
August 2012
Published version (DOI) Open Access Copy (Duke) Link to item

Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. However, whether mutant IDH1 protein is required for maintaining IDH1 mutated tumor cell growth remains unknown. Here, using a genetically engineered inducible system, we report that selective suppression of endogenous mutant IDH1 expression in HT1080, a fibrosarcoma cell line with a native IDH1(R132C) heterozygous mutation, significantly inhibits cell proliferation and decreases clonogenic potential. Our findings offer insights into changes that may contribute to the inhibition of cell proliferation and offer a strong preclinical rationale for utilizing mutant IDH1 as a valid therapeutic target.

Duke Scholars

Darell Doty Bigner
Author Darell Doty Bigner Neurosurgery
Christopher Pirozzi
Author Christopher Pirozzi Pathology
Yiping He
Author Yiping He Pathology
Giselle Yvette López
Author Giselle Yvette López Pathology
Ivan Spasojevic
Author Ivan Spasojevic Medicine, Medical Oncology
Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oncotarget

DOI

10.18632/oncotarget.577

EISSN

1949-2553

Publication Date

August 2012

Volume

3

Issue

8

Start / End Page

774 / 782

Location

United States

Related Subject Headings

  • RNA, Small Interfering
  • RNA Interference
  • Mutation
  • Isocitrate Dehydrogenase
  • Humans
  • Fibrosarcoma
  • Cell Proliferation
  • Cell Line, Tumor
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jin, G., Pirozzi, C. J., Chen, L. H., Lopez, G. Y., Duncan, C. G., Feng, J., … Yan, H. (2012). Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget, 3(8), 774–782. https://doi.org/10.18632/oncotarget.577
Jin, Genglin, Christopher J. Pirozzi, Lee H. Chen, Giselle Y. Lopez, Christopher G. Duncan, Jie Feng, Ivan Spasojevic, Darell D. Bigner, Yiping He, and Hai Yan. “Mutant IDH1 is required for IDH1 mutated tumor cell growth.” Oncotarget 3, no. 8 (August 2012): 774–82. https://doi.org/10.18632/oncotarget.577.
Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, et al. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget. 2012 Aug;3(8):774–82.
Jin, Genglin, et al. “Mutant IDH1 is required for IDH1 mutated tumor cell growth.” Oncotarget, vol. 3, no. 8, Aug. 2012, pp. 774–82. Pubmed, doi:10.18632/oncotarget.577.
Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, Spasojevic I, Bigner DD, He Y, Yan H. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget. 2012 Aug;3(8):774–782.

Published In

Oncotarget

DOI

10.18632/oncotarget.577

EISSN

1949-2553

Publication Date

August 2012

Volume

3

Issue

8

Start / End Page

774 / 782

Location

United States

Related Subject Headings

  • RNA, Small Interfering
  • RNA Interference
  • Mutation
  • Isocitrate Dehydrogenase
  • Humans
  • Fibrosarcoma
  • Cell Proliferation
  • Cell Line, Tumor
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis